Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expression of Nrf2
Authors:
Open Access
- 28 June 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 206, 107252
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (32070356)
This publication has 68 references indexed in Scilit:
- Adagrasib: First ApprovalDrugs, 2023
- Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapyActa Pharmaceutica Sinica B, 2021
- LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutationAnnals of Oncology, 2021
- Targeting the untargetable KRAS in cancer therapyActa Pharmaceutica Sinica B, 2019
- Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancerJournal of Molecular Medicine, 2018
- Nrf2-Keap1 signaling in oxidative and reductive stressBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2018
- Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategiesCancer and Metastasis Reviews, 2015
- Cyclopeptide RA-V inhibits cell adhesion and invasion in both estrogen receptor positive and negative breast cancer cells via PI3K/AKT and NF-κB signaling pathwaysBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2015
- Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagyCellular and Molecular Life Sciences, 2013
- Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21Cip1 downregulation are required for shikonin-induced apoptosisApoptosis, 2013